Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-004
Enrollment Complete in STARFAST Sports-Related Concussion Trial; Topline Results Expected This Winter GROTON, Conn., Sept. 30, 2026 /PRNewswire/ -- Astrocyte Pharmaceuticals Inc., a pioneering clinical-stage biotechnology company developing first-in-class cerebroprotective therapies for...